TORONTO, May 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign") announced today the appointment to its board of directors of Dr.
Harold S. Koplewicz, Jason D. Meretsky, and Former Senator Alfonse
"We are pleased to welcome back Senator D'Amato and be joined by our new
members, Dr. Koplewicz and Mr. Meretsky", said David Silver, the
company's Chairman. "As Biosign embarks on an exciting period of change
and growth, attracting a diverse range of leadership for our Board and
management team is critical to our success".
Harold S. Koplewicz, M.D. is the Chairman of the Board of Directors of
Delcath Systems Inc. (NASDAQ: DCTH). In 2009, he founded and became the
President of the Child Mind Institute, the only independent non-profit
organization in the USA, dedicated to transforming mental health care
for the world's children. In 2007, Dr. Koplewicz became the first Vice
Dean of External Affairs at the NYU Langone Medical Center. He has
served as a member of the National Board of Medical Examiners and as a
Commissioner of the New York State Commission on Youth, Crime and
Violence and Reform of the Juvenile Justice System. He has also served
as a member of the working group organized by the U.S. Assistant
Surgeon General and the U.S. Department of Health and Human Services to
address the effects of terrorism on children's mental health.
Jason D. Meretsky is a corporate securities lawyer with considerable
business, transactional and legal experience, particularly in the
technology sector. Mr. Meretsky previously served as Executive Vice
President, Corporate Development of Avid Life Media Inc. and Vice
President and General Counsel of Enghouse Systems Limited. (TSE: ESL).
Mr. Meretsky serves on the board of directors and Audit Committee of
Homeserve Technologies Inc. (previously listed on the TSX), the Board
of Directors of CECO Environmental Inc. (Nasdaq: CECO), and a director
and senior officer of LiveReel Media Corporation (OTCBB:LVRL). Mr.
Meretsky previously practiced corporate and securities law as a partner
with Goodman and Carr LLP. He is a member in good standing of the
Canadian Bar Association and the Law Society of Upper Canada.
Former Senator Alfonse D'Amato had a distinguished 18-year career in the
U.S. Senate, served as chairman of the Senate Banking Committee, was a
member of the Senate Appropriations Committee and served on the Senate
Finance Committee. Senator D'Amato is a current board member for
Signature Bank (Nasdaq: SBNY), and he is Chairman of the Board for the
Poker Players Alliance, an industry group that supports a repeal of the
restrictive US internet gambling laws. From 1999 to 2009, he was a
member of the board of CA Technologies (Nasdaq: CA), where he served on
both the audit and the compensation committees, and he is a former
director of Cendant Corporation.
In addition to these new appointments, Biosign announced the departure
of two directors, Tony LaVista and Mouane Sengsavang, to focus on prior
business commitments. "On behalf of the entire organization, we would
like to express our sincere thanks to Tony and Mouane, both of whom
made significant contributions to Biosign during their tenure on the
Board", said Dr. Radu Leca, Biosign's Founder and CEO. "Special thanks
are extended to Tony, who has served, since 2008, with great abnegation
and competence, as Chair of Biosign's Audit Committee", added Leca.
The new Board, consisting of Radu Leca, David Silver, Harold Koplewicz,
Jason Meretsky, and Alfonse D'Amato, is expected to further increase
the company's capability to realize its commercial opportunities.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
| Biosign Contact Information || || || || || |
| || || || || |
| Colley Clarke |
Phone: (416) 218-9800 ext. 234
| || || || || Alan S. Roemer |
The Trout Group
Phone: (646) 378-2945